 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...3031323334353637383940...9091» |
- Targeted gene sequencing of H. pylori from FFPE gastric biopsies, to detect antimicrobial resistance (C / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3492;
- Establishment of MALDI-TOF database for Helicobacter pylori (B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3357;
- Comparative study on the performance of single cell counting method for the detection of antimicrobial ssusceptibility of Gram-negative bacteria (B / 01) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3310;
- Identifying confounding factors within a biofilm disruption assay using crystal violet (B / 01) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3302;
- Impact of inoculum variation on the minimum inhibitory concentration of Mycobacterium tuberculosis using the reference EUCAST broth microdilution method against multiple antimycobacterial agents (B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3271;
- levofloxacin / Generic mfg.
Multi-centre evaluation of Pseudomonas species with updated EUCAST v12.0 levofloxacin breakpoints for commercial dried Gram-negative MIC panels (B / 03) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3268;
- Clinical manifestations, antimicrobial resistance and genomic feature analysis of the multidrug resistant Elizabethkingia strains (B / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3246;
- Emergence and clonal expansion of Aeromonas hydrophila ST1172, that simultaneously producing produces MOX-13 and OXA-724 (B / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3240;
- tetracycline / Generic mfg.
Evaluation of short-term antimicrobial therapy with a combination of tetracyclines and fluoroquinolones for Japanese spotted fever (B / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3211;
- Human infections caused by Streptococcus canis : case series (B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_3156;
- Outcomes and predictors of clinical failure in Stenotrophomonas maltophilia infections in a tertiary care center: a retrospective observational study (A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2971;
- Bloodstream infections in Europe and United States: aetiology and antimicrobial susceptibility results from the SENTRY antimicrobial surveillance programmme (2019 (A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2961;
- Potential concordance between surveillance culture isolates and organisms causing bacteraemia in haematological patients (A / 09) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2959;
- Molecular epidemiology of Klebsiella pneumoniae environmental isolates from a tertiary care hospital in Mexico (C / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2607;
- Carbapenem-resistant Acinetobacter causing osteomyelitis and periprosthetic infections (C / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2471;
- Using whole genome sequencing (WGS) to predict antimicrobial resistance (AMR) in the opportunistic pathogens Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa (B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2346;
- Genome-wide associations identify genetic markers for fluoroquinolone resistance levels in Escherichia coli from livestock animals (B / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2344;
- Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical isolates (B / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2304;
- Quantifying the effects of antibiotic resistance gene presence on antibiotic susceptibility phenotypes in Escherichia coli (B / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2289;
- Baxdela (delafloxacin) / Menarini, Melinta Therap
The importance of Glu-84 ParC in the resistance to delafloxacin in Staphylococcus aureus (B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2276;
- levofloxacin / Generic mfg., clarithromycin / Generic mfg., amoxicillin / Generic mfg.
In vitro bactericidal activity of amoxicillin combined to clarithromycin or levofloxacin on clinical strains of Helicobacter pylori (B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2274;
- In vitro efficacy of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori (B / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2273;
- Novel microfluidic system for antimicrobial susceptibility testing (B / 02) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2165;
- Emrok (levonadifloxacin) / Wockhardt
Clinical isolates of novel species of Stenotrophomonas sepilia are highly susceptible to novel benzoquinolizine quinolone agent levonadifloxacin (B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2148;
- Comparison of Ureaplasma Antibiotic Susceptibility Testing Using the Mycoplasma System Plus II and CLSI Methodology (B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2141;
- Toxigenic and non-toxigenic Vibrio cholerae can share the same MIC breakpoints (B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2132;
- Testing antibiotic tolerance of Staphylococcus aureus for clinical practice (B / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2127;
- Characterisation of Acidaminococcus intestini infections (B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2120;
- Evaluation of EUCAST RAST from positive blood culture in comparison with Vitek 2 system in cancer patients from tertiary care hospital in resource limited settings (B / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2111;
- aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie
In vitro (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2096;
- Virulence and resistance of Pseudomonas aeruginosa isolated from poultry (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2095;
- Evolution of primary antimicrobial resistance among Helicobacter pylori in Belgium from 2013 to 2021 (A / 16) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2089;
- Isolation of carbapenem-resistant Pseudomonas aeruginosa from Guanay Cormorants ( Phalacrocorax bougainvillii ) from Isla Pescadores, Lima, Peru (A / 15) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2068;
- Transferable quinolone resistance determinants in carbapenemase-producing Enterobacterales (A / 14) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2050;
- Spread of multidrug-resistant Pseudomonas aeruginosa ST3079 clone harbouring bla GES-1 and bla KPC-2 during the SARS-CoV-2 pandemic (A / 14) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2049;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vitro activity of ceftazidime-avibactam and comparator agents against MDR Pseudomonas aeruginosa , ATLAS Global Surveillance Program 2017-2021 (A / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2037;
- Antibiotic resistance profile of Helicobacter pylori cultivation from gastric biopsies (A / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2002;
- Phenotypic and genotypic antibiotic susceptibility profiles of Pseudomonas aeruginosa from cystic fibrosis patients in South Africa (A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1990;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
In vitro activity of ceftazidime/avibactam against Gram-negative bacteria collected from Croatia, Czech Republic, Hungary, Israel, Lithuania, Poland and Romania: ATLAS surveillance programme 2018, 2019, 2020 (A / 11) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1989;
- aztreonam/avibactam (PF-06947387) / Pfizer, AbbVie
In vitro activity of aztreonam-avibactam and comparator agents against clinical Enterobacterales isolates collected worldwide stratified by global region, ATLAS Global Surveillance Program, 2017-2021 (A / 08) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1938;
- Phenotypic and molecular characterisation of Vibrio cholerae non-O1/non-O139 strains from Germany and other European countries (A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1919;
- Antimicrobial susceptibility of Gram-negative bacteria from China, the study for monitoring of antimicrobial resistance trends (SMART): from 2019 to 2020 (A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1910;
- Outbreak of Serratia marcesens co-producing NDM-1 plus OXA-48-like carbapenemases in an interzonal general hospital (A / 07) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1902;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD)
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative pathogens before and during the COVID-19 pandemic: SMART United States 2018-2021 (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1898;
- gepotidacin (GSK2140944) / GSK
In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019-2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1889;
- Drug resistance profiles of biofilm-producing isolates of Achromobacter , Burkholderia , and Stenotrophomonas species (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1882;
- Pseudomonas aeruginosa in pediatric patients with cystic fibrosis: clinical features, antibiotic susceptibility results, antibiotic resistance genes and molecular typing (A / 06) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1881;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016-2019 in China (A / 05) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1877;
- In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020 (A / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1851;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Activity of ceftolozane/tazobactam and comparators against clinical Gram-negative pathogens and resistant phenotypes: SMART United States 2019-2021 (A / 04) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_1843;